Company: SNSE
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001193125-25-140329
Chunk: 1

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 5.03
Chunk 1
---
 will be reduced proportionately.

No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof. The Reverse Stock Split will affect all stockholders proportionately and will not affect any stockholder’s percentage ownership of the Company’s common stock (except to the extent that the Reverse Stock Split results in any stockholder owning only a fractional share).

The Company’s common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on June 17, 2025. The new CUSIP number for the Company’s common stock following the Reverse Stock Split is 81728A207.

The foregoing description is qualified in its entirety by the Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-Kand is incorporated herein by reference.